Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Lawrence BlondeLidia BelousovaUdi FainbergPedro A Garcia-HernandezSunil M JainMargit S KaltoftOfri MosenzonJalal NafachMads Sundby PalleRosangela Rea

Published in: Diabetes, obesity & metabolism (2020)

Liraglutide significantly improved glycaemic control compared with placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings.

Keyphrases

double blind
placebo controlled
type diabetes
clinical trial
phase iii
phase ii
study protocol
insulin resistance
randomized controlled trial
metabolic syndrome
adipose tissue
weight loss